MannKind soars as FDA panel backs its inhaled insulin product

(Reuters) - MannKind Corp's shares doubled on Wednesday, after an advisory committee to the U.S. health regulator recommended approval of the drug developer's inhaled insulin treatment. Analysts said the drug, Afrezza, is likely to win approval in its third attempt, but noted that MannKind would still have to conduct postmarket studies to demonstrate its long-term safety profile. "If approved, Afrezza will require quite extensive post-marketing surveillance to monitor lung cancer and pulmonary function. Given the costs involved, this could keep some (potential partners) at bay," MLV & Co analyst Graig Suvannavejh said in a note. via Health News Headlines - Yahoo News Read More Here..